CNA Staff, Jun 12, 2023 / 13:45 pm
England’s National Health Service has announced it is limiting the use of puberty-blocking drugs for minors and will allow them only “as part of clinical research” following an evaluation of medical practices for purported “gender transitions.”
Its interim policy, announced June 9, proposes that “puberty-suppressing hormones (GnRH analogues) are ‘not routinely commissioned’ as there is not enough evidence to support their safety or clinical effectiveness as a routinely available treatment and that they should only be accessed as part of research.”
The NHS document advises that “outside of a research setting, puberty-suppressing hormones should not be routinely commissioned for children and adolescents who have gender incongruence/dysphoria.”
Gender dysphoria is the perception that one’s birth sex does not match one’s perceived gender identity.